JAMA Oncology

JAMA Oncology JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed publications.

A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on ...
08/14/2026

A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity.

What is your diagnosis? https://ja.ma/3S9uzY5

Among patients with early undergoing molecular residual disease surveillance, tissue-free detection was strongly pro...
08/13/2026

Among patients with early undergoing molecular residual disease surveillance, tissue-free detection was strongly prognostic for recurrence.

The assay identified recurrence risk with high accuracy and may support testing when archival tumor tissue is unavailable. https://ja.ma/4wkrz9l

Among men with initiating concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, newly do...
08/13/2026

Among men with initiating concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, newly documented metabolic abnormalities accumulated rapidly during the first year of treatment.

was frequently documented soon after treatment initiation, with hypertension the most common component outcome, supporting early metabolic monitoring during cancer care. https://ja.ma/3TQHOxv

Among patients with metastatic , alert-based digital patient-reported outcome monitoring was associated with lower fati...
08/12/2026

Among patients with metastatic , alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference.

https://ja.ma/3THtPKt

A single-fraction 19 Gy SBRT regimen for localized achieved 92.9% 3-year biochemical relapse-free survival, with grade...
08/12/2026

A single-fraction 19 Gy SBRT regimen for localized achieved 92.9% 3-year biochemical relapse-free survival, with grade 2 genitourinary and gastrointestinal adverse event rates below 10% and 5%, respectively, at 3 years.

https://ja.ma/461FSEZ

Patients with aged 15 to 39 who received medical assistance in dying experienced escalating symptoms and often receive...
08/12/2026

Patients with aged 15 to 39 who received medical assistance in dying experienced escalating symptoms and often received palliative care later in the disease course compared to the general cancer population.

https://ja.ma/4qlT2WT

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to...
08/12/2026

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone.

https://ja.ma/4wr1SnQ

Kirsten Bibbins-Domingo, PhD, MD, MAS, has extended her contract with the American Medical Association to lead JAMA and ...
08/10/2026

Kirsten Bibbins-Domingo, PhD, MD, MAS, has extended her contract with the American Medical Association to lead JAMA and the JAMA Network through 2031. The agreement provides continuity for one of the world's leading medical publishing platforms that includes JAMA, JAMA Network Open, and 11 specialty journals.

Under Dr Bibbins-Domingo’s leadership, the JAMA Network has expanded initiatives in scientific communication, audience engagement, and professional development, including the JAMA Summit, JAMA+ AI, JAMA+ Women's Health, JAMA+ Trials, international author outreach, and fellowship opportunities for early-career authors and reviewers.

The extension supports continued leadership for clinicians, researchers, and policymakers who rely on the JAMA Network's trusted medical evidence.

đź”— Read the full press release: https://ja.ma/3Spbam9

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to...
08/10/2026

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone.

https://ja.ma/45MI6rP

In patients with receiving , mathematical biomarkers from first-cycle prostate-specific antigen ( ) dynamics predicte...
08/09/2026

In patients with receiving , mathematical biomarkers from first-cycle prostate-specific antigen ( ) dynamics predicted time to progression and overall survival better than standard PSA metrics.

https://ja.ma/4wdXxE8

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category